Icatibant Accord (Icatibant)

Icatibant is used to manage hereditary angioedema by targeting the bradykinin pathway.

• Acute hereditary angioedema attacks (C1‑INH deficiency): rapid relief of swelling and pain.
• Hereditary angioedema type I attacks: fast reduction of edema in skin and mucosal tissues.
• Hereditary angioedema type II attacks: prompt control of life‑threatening airway swelling.

• Icatibant selectively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin from binding and activating its signaling cascade. By inhibiting this receptor, the drug stops bradykinin‑induced vasodilation and increased vascular permeability, which are responsible for the rapid swelling seen in hereditary angioedema attacks. The antagonism is competitive and reversible, allowing normal physiological bradykinin activity to resume after the drug is cleared.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration and pharmacologic activity.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or erythema: localized skin reddening.
• Swelling at injection site: transient edema.
• Headache: mild headache.
• Nausea: occasional feeling of nausea.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring emergency care.
• Angioedema of the airway: swelling that may compromise breathing.
• Severe hypotension: sudden drop in blood pressure.
• Thrombocytopenia: low platelet count.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Cardiovascular collapse: rare life‑threatening event.

Before using Icatibant, clinicians should consider several safety precautions to minimize risks.

• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown excretion; weigh benefits against potential infant exposure.
• Renal impairment: no dosage adjustment required, but monitor for accumulation.
• Concomitant ACE inhibitors: may increase bradykinin levels; monitor for angioedema.
• Hypersensitivity: discontinue immediately if severe allergic reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid)

• ACE inhibitors: combined use may heighten risk of angioedema.
• Angiotensin receptor blockers (ARBs): may potentiate bradykinin effects, increasing swelling risk.

Moderate Interactions (Monitor Closely)

• Estrogen‑containing oral contraceptives: may affect frequency of HAE attacks; monitor clinical response.
• Neprilysin inhibitors (e.g., sacubitril): increase bradykinin levels; observe for enhanced edema.
• Immunosuppressants: no direct pharmacokinetic interaction, but infection risk may complicate HAE management.